The Working Group on Trends in the Demand for Blood Products noted in its July meeting that the size of the population with haemophilia could rise significantly. They also said: "It was apparent that clinicians were coming to recognise the supply problems; eg, they were moderating their demands for Factor VIII for prophylactic treatment."